Back to Authors

Straley, Kimberly

A5050943295 | I4210092565

Mayo Clinic

Agios Pharmaceuticals (United States)

Citations 1

Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia

Blood | May 3, 2013 | Volume: 121 | Issue: 24 | Pages: 4917-4924

10.1182/blood-2013-03-493197 | PMID 23641016

Key Points Serum 2HG analysis by LC-MS can accurately identify patients with AML with and without IDH mutations. Oncometabolite testing of serum 2HG is indicated as a diagnostic, prognostic, and therapeutic monitoring tool in AML.